Signal from the log
Acta Pharmaceuticals
24 M$ · Seed · United States · Biotech
Acta Pharmaceuticals développe GSM-779690T, un modulateur oral de la gamma-sécrétase qui réduit la forme du peptide amyloïde qui forme les plaques, pour intervenir tôt dans la maladie d'Alzheimer ; la phase 1 est ouverte. Les 24 M$ sont le total de son seed, sans chef de file nommé.
Verified
Announced on , logged by the watch of 15 October 2026.
- Operation
- Funding round
- Announced amount
- 24 M$
- Stage
- Seed
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
With Alzheimer's Disease Research Foundation , Dolby Family Ventures , Gamma Bio Investors
Provenance
Source businesswire
Logged on 15 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.